Safe Pro Group Inc. (NASDAQ: SPAI)

The QualityStocks Daily Newsletter would like to spotlight Safe Pro Group Inc. (NASDAQ: SPAI).

Safe Pro Group (NASDAQ: SPAI) , an AI-enabled defense and security solutions provider, announced it successfully completed a U.S. Army live fire exercise where its patented AI technology processed drone imagery at the edge to detect live scattered mines and deliver actionable intelligence to commanders. The exercise builds on a prior government contract and supports the rollout of the company’s NODE-X edge computing system, which leverages its SPOTD AI platform trained on millions of real-world images to identify explosive threats, generate 3D terrain models and enhance battlefield situational awareness, as Safe Pro continues engagement with Army stakeholders and prepares for additional exercises in the second quarter of 2026.

To view the full press release, visit https://ibn.fm/paSeN

Safe Pro Group Inc. (NASDAQ: SPAI) is a mission-driven technology company delivering advanced AI-powered security and defense solutions. It is focused on serving customers in the defense, homeland security, humanitarian, law enforcement, and commercial markets where its AI, drone-based services and ballistic protective gear can synergistically deliver safety and operational efficiency.

At the heart of Safe Pro’s mission is its patented artificial intelligence (AI), machine learning (ML), deep learning and applied computer vision software technology. These tools are currently being used to rapidly detect small objects in drone-based video and imagery such as landmines and unexploded ordnance (UXO), enabling safer and more efficient field operations across global conflict and post-conflict zones and supporting efforts to improve the reliability of critical infrastructure. The company’s vision is to lead the evolution of security and threat detection through AI innovation, while its mission is to empower governments, enterprises, and humanitarian organizations with tools to respond to evolving threats at scale.

With a team of leaders and subject matter experts drawn from the defense, technology, and public safety sectors, Safe Pro Group delivers U.S.-developed next-generation AI and drone services through its Safe Pro AI and Airborne Response units and high-performance, American-made ballistic protective solutions through its Safe-Pro USA subsidiary.

The company is headquartered in Aventura, Florida.

Products

Safe Pro Group’s three business units operate across software, hardware, and field services to deliver a comprehensive suite of solutions. Each division plays a distinct role in supporting defense, humanitarian and public safety missions around the world.

Safe Pro AI

Safe Pro AI’s core AI-powered computer vision technology enables the rapid analysis of drone-based imagery to autonomously detect objects of interest. Its flagship product, SpotlightAI™ can detect and label over 150 types of explosive threats including landmines, cluster munitions, and unexploded ordnance (UXO). Built on more than two years of real-world usage in Ukraine and now including additional imagery being gathered from the Asian-Pacific region and Africa, SpotlightAI™ rapidly processes and creates high-resolution maps supported by the hyper scalability of the Amazon Web Services (AWS) cloud or detects threats in real-time locally through its OnSite Windows-based software application. Today, the platform boasts one of the world’s largest datasets built on over 1.6 million real-world battlefield images from Ukraine, identifying 28,000+ threats across more than 6,750 hectares, an area equivalent in size to Manhattan.

Airborne Response

Airborne Response is a leading provider of mission critical drone services using U.S. Government-compliant small uncrewed aircraft systems (sUAS) (drones). It serves enterprises in utilities & telecom and insurance with a full-range of drone-based critical infrastructure inspection and monitoring solutions as well as Drone-as-a-First Responder (DFR) services for law enforcement and public safety. It provides customers with actionable intelligence though data capture, analytics and processing powered by AI.

Safe-Pro USA

Safe-Pro USA manufactures ultra-premium, American-made ballistic protection systems including advanced body armor and ballistic plates as well as complete Explosive Ordnance Disposal (EOD) suits, demining aprons, and bomb blankets. All products exceed U.S. and NATO standards and are designed, engineered, and produced in the U.S., supporting customers across military, humanitarian, and law enforcement sectors.

Market Opportunity

Harnessing its patented, real-time, AI-powered processing of drone-based imagery, Safe Pro is creating a uniquely powerful ‘Next-Gen’ approach to situational awareness supporting ground-based personnel in safely completing their defense/military, humanitarian, law enforcement & commercial missions.

The global threat posed by landmines and UXO spans nearly 60 countries, affecting millions of civilians and imposing significant economic burdens, particularly in agriculture and infrastructure. In Ukraine alone, the contamination of 17 million hectares has resulted in $50+ billion in agricultural losses, with World Bank estimates projecting $30 billion needed in demining costs. According to the Landmine Monitor 2024, regions in Asia, Africa, and Latin America continue to report high casualty rates.

Safe Pro is positioned to capture a portion of the $15 billion+ global defense tech market, especially in AI-driven battlefield intelligence, drone surveillance, and threat detection. As a U.S.-based AI and defense technology provider with a HUBZone-certified manufacturing arm, Safe Pro is eligible for federal and state procurement programs, public safety grants, and critical infrastructure contracts, as well as global humanitarian demining efforts.

Leadership Team

Dan Erdberg, Chairman and CEO, brings over 20 years of experience as a C-level technology executive. He has led multiple Nasdaq listings in the drone, 5G, and satellite communications sectors, raised over $50 million in growth capital, and spearheaded Safe Pro Group’s corporate strategy and acquisitions.

Theresa Carlise, Chief Financial Officer, has more than 30 years of experience in financial leadership roles for public companies. Her expertise includes equity transactions, strategic planning, and financial restructuring. She served as Chief Financial Officer, Secretary, Treasurer and Director of various publicly traded companies within the retail, telecommunications, distribution, transportation, mortgage banking and construction sectors.

Pravin Borkar, CTO and Director (President, Safe-Pro USA), has over 30 years of experience in the engineering and manufacturing of ballistic protection systems for the U.S. Department of Defense. He has developed armor solutions for personnel and aircraft platforms including the CH-53 and Blackhawk.

Christopher Todd, President (Airborne Response), is a drone industry veteran and Certified Emergency Manager (CEM®) with more than 30 years of experience. He founded Airborne Response and is President of AUVSI Florida, with expertise in public safety drone deployment and emergency response.

Safe Pro Group Inc. (NASDAQ: SPAI), closed Wednesday's trading session at $4.35, up 6.0976%, on 202,212 volume. The average volume for the last 3 months is 222,393 and the stock's 52-week low/high is $1.96/$9.1599.

Recent News

• Safe Pro Group Inc. (NASDAQ: SPAI) - https://www.investorbrandnetwork.com/newsarticle/?qmodStoryID=5507516941635161
• DefenseNewsBreaks - Safe Pro Group Inc. (NASDAQ: SPAI) Launches Commercial Rollout of NODE-X AI Edge Processor for Military Missions
• DefenseNewsBreaks - Safe Pro Group Inc. (NASDAQ: SPAI) Launches NODE-X AI Edge Processor for Drone Threat Detection

BluSky AI Inc. (OTC: BSAI)

The QualityStocks Daily Newsletter would like to spotlight BluSky AI Inc. (OTC: BSAI).

BluSky AI (OTC: BSAI) is positioning at the forefront of a major shift in artificial intelligence infrastructure, where flexibility and predictable access to compute resources are becoming mission critical. “With AI workloads increasing at unprecedented rates, organizations are changing their outlook on traditional hyperscale cloud providers and finding alternatives that reduce vendor lock-in, provide the compute that is quickly becoming unavailable, while enhancing cost visibility and performance reliability. The company’s approach, anchored in the design of modular and quickly deployable data centers, offers a compelling solution for this evolving landscape,” a recent article reads.

“BluSky AI is speeding up the rollout of its SkyMod data centers, a next-gen infrastructure platform created mainly for AI workloads. These scalable AI factories are created to deliver high-performance GPU compute using faster deployment timelines in months compared to years with conventional data center builds. By cutting down time-to-market, the company enables startups, enterprises, and academic institutions to access the needed infrastructure without the bottlenecks associated with hyperscale expansion.”

To view the full article, visit https://ibn.fm/fMXjV

BluSky AI Inc. (OTC: BSAI) is pioneering the next generation of AI infrastructure through modular, rapidly deployable data centers that meet the escalating compute demands of artificial intelligence, machine learning, and high-performance computing. The company’s mission is to empower AI innovators by eliminating infrastructure bottlenecks and accelerating time-to-compute with energy-efficient, scalable solutions.

Rather than betting on individual AI applications, BluSky AI addresses the universal need for compute power—positioning itself as a foundational layer in the AI revolution. Its infrastructure-first approach enables clients to focus on innovation while the company delivers the critical backbone powering tomorrow’s breakthroughs.

BluSky AI is headquartered in Salt Lake City, Utah.

Products

BluSky AI’s core offering is its SkyMod series of modular data centers—pre-assembled, scalable compute units designed specifically for AI workloads. The flagship SkyMod One delivers 1 MW of compute power in a compact 1,400-square-foot footprint, while the SkyMod XL offers 1.7 MW in 3,000 square feet. These units are fully assembled off-site, tested, and shipped ready for plug-and-play deployment either on BluSky-owned land or client facilities.

SkyMod modules integrate NVIDIA GPUs and are optimized for high-density AI applications such as generative AI, large language models, inference engines, and scientific computing. Built for rapid scaling and high efficiency, each system includes advanced cooling, secure infrastructure, and dynamic workload balancing to support evolving client needs.

The company’s data centers are engineered for sustainability, incorporating renewable energy sources like solar, wind, and geothermal where available. By deploying on powered land assets, BluSky AI shortens lead times and lowers costs, creating a fast, flexible alternative to traditional monolithic data centers.

Market Opportunity

The global data center market was valued at $347.6 billion in 2024 and is projected to reach $652.0 billion by 2030, growing at a CAGR of 11.2%, driven by the rapid expansion of AI, machine learning, and IoT adoption, according to Grand View Research. As enterprises demand faster, more scalable compute solutions, modular infrastructure like BluSky AI’s SkyMod series offers a compelling alternative to legacy data center models.

With North America accounting for over 40% of the global market and the U.S. expected to grow at a 10.7% CAGR from 2025 to 2030, BluSky AI is well-positioned to capture demand for AI-optimized infrastructure that can be deployed rapidly and cost-effectively. By focusing on GPU-centric, modular deployments tied to energy infrastructure, the company addresses a growing gap between compute demand and deployment speed in the AI era.

Leadership Team

Trent D’Ambrosio, Chief Executive Officer, is a seasoned executive with a track record in telecommunications, hedge fund management, and natural resource development. He previously sold the first transatlantic fiber cable, built a successful gold mining company, and now leads BluSky AI with a vision to revolutionize AI infrastructure through strategic energy integration and rapid deployment.

Julien Bedard, Chief Technology Officer, is a pioneering technologist known for launching the first Bitcoin escrow and anti-fraud service. At BluSky AI, he oversees cloud architecture, cybersecurity, infrastructure automation, and the development of AI-native data center technology, ensuring scalability and resilience across deployments.

Dan Gay, Chief Operating Officer, has Fortune 500 executive leadership in telecom, technology, and energy, as well as start-up experience with finance and blockchain companies. At MCI and Qwest, he launched new service and sales centers, and directed National Account Sales. He has been a successful CMO in brand creation, product development, partnerships, and revenue generation programs to expand company awareness, sales, and revenue.

BluSky AI Inc. (OTC: BSAI), closed Wednesday's trading session at $3.9, up 5.4054%, on 677 volume. The average volume for the last 3 months is 220 and the stock's 52-week low/high is $0.0003/$17.97.

Recent News

• BluSky AI Inc. (OTC: BSAI) - AINewsBreaks - BluSky AI Inc. (BSAI) Expands Scalable Compute Access with Next-Gen Platform
• BluSky AI Inc. (BSAI) Outlines Strategy to Tackle GPU Bottlenecks with Modular Distributed Neocloud Infrastructure
• AINewsBreaks - BluSky Ai Inc. (OTCID: BSAI) Featured in Research Report Highlighting Scalable GPU-Centric AI Platform

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT)

The QualityStocks Daily Newsletter would like to spotlight LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT).

• For a long time, proton therapy wasn’t available for many cancer patients due to the footprint of traditional proton therapy equipment and the high costs associated with it.
• However, the size and cost of this equipment is shrinking, opening it up as a more viable treatment option for cancer patients.
• Liora Technologies, a subsidiary of LIXTE Biotechnology Holdings, Inc., is poised to offer compact, precise, and accessible proton therapy through the innovative Linac for Image Guided Hadron Therapy (“LiGHT”) System.

Proton therapy is a specialized cancer treatment that uses precision-guided radiation beams to target and destroy tumors while limiting harm to surrounding healthy tissue. While it has been around for decades, it’s been largely inaccessible for many cancer patients due to both the huge footprint of traditional proton therapy equipment and the high costs. However, some programs have recently turned their heads to proton therapy and are attempting to make it more accessible for those who can benefit from it. For example, Stanford School of Medicine recently opened a new facility that offers proton therapy that’s more accessible than in the past. Working alongside medical tech companies, the university was able to shrink down the size and cost of the proton therapy equipment, making it easier for more people to access. In addition to Stanford, companies such as Liora Technologies are also looking to make proton therapy a more accessible and viable treatment option for the patient population. Liora Technologies, a UK-based subsidiary of LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT), that is pioneering the electronically controlled therapy that represents a shift in proton delivery.

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) is a clinical-stage pharmaceutical company developing differentiated cancer therapies built around a novel biological target. Rather than introducing standalone treatments, the company is focused on advancing a first-in-class approach designed to enhance the effectiveness of established cancer therapies, addressing persistent challenges that continue to limit outcomes in oncology.

LIXTE’s work centers on improving how chemotherapy and immunotherapy perform in difficult-to-treat cancers with significant unmet medical need. By translating a distinct scientific concept into therapies that can be integrated into existing treatment frameworks, the company aims to expand the reach and impact of current standards of care without requiring wholesale changes to clinical practice.

Alongside internal development, LIXTE has pursued selective strategic actions that extend its capabilities beyond drug development, supporting its evolution into a platform-oriented oncology company spanning both pharmaceutical and technology-driven approaches.

The company is headquartered in Boca Raton, Florida.

Portfolio

LB-100 (PP2A Inhibitor Platform)

LIXTE’s lead clinical candidate, LB-100, is a proprietary small-molecule inhibitor of protein phosphatase 2A (PP2A) designed to enhance the activity of chemotherapy and immunotherapy. The compound has demonstrated a favorable safety profile in Phase 1 clinical trials and has been supported by more than 25 published preclinical and translational studies. LB-100 is currently being evaluated in multiple clinical programs targeting solid tumors with limited treatment options.

Ongoing trials include combinations of LB-100 with immunotherapy in ovarian clear cell carcinoma and metastatic MSI-low colon cancer, as well as combination therapy with chemotherapy in advanced soft tissue sarcoma. These studies are being conducted in collaboration with leading academic cancer centers and industry partners, reflecting LIXTE’s emphasis on externally validated clinical execution.

Radiotherapy Platform Expansion (Liora Technologies)

In November 2025, LIXTE expanded beyond pharmaceuticals with the acquisition of Liora Technologies Europe Ltd., adding an electronically controlled proton therapy platform known as the LiGHT System. This acquisition established LIXTE’s entry into radiotherapy, complementing its drug development activities and creating optionality for future recurring revenue models tied to jointly operated treatment centers.

Market Opportunity

LIXTE is targeting cancers where existing therapies show limited durability due to resistance, toxicity constraints, or suboptimal patient response. Chemotherapy and immunotherapy are widely applicable across tumor types but remain constrained by these factors, creating an opportunity for approaches that improve efficacy without proportionally increasing toxicity.

The company’s clinical programs focus on ovarian clear cell carcinoma, metastatic colon cancer, and advanced soft tissue sarcoma, indications characterized by high unmet need and limited effective treatment options. Rather than reshaping oncology care, LIXTE is developing LB-100 to augment existing therapies, an approach that could support wider clinical use within established treatment pathways.

Leadership Team

Geordan Pursglove, Chairman, President and Chief Executive Officer, is an accomplished executive and entrepreneur with more than a decade of experience spanning mergers and acquisitions, capital markets, strategic growth initiatives, and operational leadership across both public and private companies. His background includes leadership roles across technology, logistics, customer experience, sports, and marketing, with a focus on scaling organizations, raising capital, and executing transformative strategies.

Bas van der Baan, Chief Scientific Officer, has more than 20 years of experience in biotechnology with a concentration in oncology and diagnostics. He previously served as Chief Clinical and Business Development Officer at Agendia, where he played a key role in initiating and executing clinical trials that supported the commercialization of precision molecular oncology diagnostics in both the U.S. and Europe.

Peter Stazzone, Chief Financial Officer, brings over two decades of financial management experience across publicly traded and privately held companies. His background includes leading capital raises, mergers and acquisitions, financial controls, and public company reporting, with prior CFO roles at companies including Beyond Commerce, Strainz, and Voice Telecom.

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT), closed Wednesday's trading session at $3.11, up 6.8729%, on 50,493 volume. The average volume for the last 3 months is 42,554 and the stock's 52-week low/high is $0.64/$6.26.

Recent News

• LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) - Compact Proton Therapy Delivery Helps Make the Treatment More Accessible for Cancer Patients
• BioMedNewsBreaks - LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Reports Interim Ovarian Cancer Trial Results at SGO Conference
• LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Accelerates Cancer Care Innovation with Liora Technologies Acquisition and Leadership Expansion

CNS Pharmaceuticals Inc. (NASDAQ: CNSP)

The QualityStocks Daily Newsletter would like to spotlight CNS Pharmaceuticals Inc. (NASDAQ: CNSP).

Canadian scientists have made an unexpected finding about glioblastoma, one of the deadliest and hardest-to-treat forms of brain cancer. Cells previously regarded as passive support structures in healthy brain tissue have been found to actively fuel tumor growth through signaling that boosts cancer cell function. The discovery also points toward a drug already in wide clinical use that may be capable of interrupting that process. Both findings represent meaningful advances in a field that has seen very limited therapeutic progress over several decades. Glioblastoma carries one of oncology’s bleakest prognoses, with survival following diagnosis typically measured in months rather than years. Patients have access to very few effective treatment options, and the outlook has changed little over recent decades. Rather than operating as a self-contained mass, glioblastoma depends heavily on support from surrounding brain tissue. Identifying which neighboring cells enable that support has long been a difficult research problem. Singh contends that probing that communication network has revealed a point of weakness that an approved medication may be able to reach. Jason Moffat, co-senior author and head of Genetics and Genome Biology at SickKids, regards the tumor’s internal environment as more active and complex than the field had understood, and views the CCR5 pathway as a credible candidate for clinical exploration. This study extends a 2024 paper by the same research groups, published in Nature Medicine, which showed that glioblastoma can exploit molecular channels that serve developmental functions in healthy brains. Taken together, the two bodies of work suggest that severing the cellular communication a tumor depends on for its survival, rather than targeting malignant cells in isolation, may offer a more durable and, hopefully, more effective route against a cancer that has long resisted conventional treatment. The rush to develop effective therapies against glioblastoma is gaining momentum, and entities like CNS Pharmaceuticals Inc. (NASDAQ: CNSP) are working tirelessly to bring to market new treatments that move the dial in the fight against this deadly type of brain cancer. As more insights about what drives this cancer come to light, the outlook for the commercialization of novel treatments keeps improving. 

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is a clinical stage biotechnology company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system.

The company was founded in 2017 and is headquartered in Houston, Texas.

Organ Targeted Therapeutics

The company’s lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Berubicin also has potential to treat other central nervous system malignancies. Based on limited clinical data, Berubicin appears to be the first anthracycline to cross the blood brain barrier in the adult brain, and it was the subject of a successful Phase 1 study which found the MDT and produced efficacy data as well.

CNS holds a worldwide exclusive license to the Berubicin chemical compound. The company has acquired all requisite data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase I clinical trial of Berubicin in malignant brain tumors. In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. In 2017, CNS entered into a collaboration and asset purchase agreement with Reata.

CNS intends to explore the potential of Berubicin to treat other diseases, including pancreatic and ovarian cancers and lymphoma. The company is also examining plans to develop combination therapies that include Berubicin.

CNS estimates that more than $25 million in private capital and grants were invested in Berubicin prior to the company’s $9.8 million IPO in November 2019.

CNS intends to submit an IND for Berubicin during the fourth quarter of 2020 and expects to commence a Phase II clinical trial of Berubicin for the treatment of GBM in the U.S. in Q1 2021. A sub-licensee partner was awarded a $6 million EU/Polish National Center for Research and Development grant to undertake a Phase II trial of Berubicin in adults and a first-ever Phase I trial in pediatric GBM patients in Poland in 2021.

The company’s second drug candidate, WP1244, is a novel DNA binding agent licensed from the MD Anderson Cancer Center. In preclinical studies, WP1244 proved to be 500-times more potent than the chemotherapeutic agent, daunorubicin, in inhibiting tumor cell proliferation. The company has entered into a sponsored research agreement with the MD Anderson Cancer Center to further the development of WP1244.

CNS Pharmaceuticals recently engaged U.S.-based Pharmaceutics International Inc. and Italian BSP Pharmaceuticals SpA for the production of the Berubicin drug product. The company has implemented a dual-track manufacturing strategy to mitigate COVID-19-related risks, diversify its supply chain and provide for localized availability of Berubicin. CNS has already completed synthesis of Berubicin’s active pharmaceutical ingredient (API) and has shipped the API to both manufacturers in order to prepare an injectable form of Berubicin for clinical use.

Global Brain Tumor Therapeutics Market

The high recurrence rate of malignant brain tumors is due to reappearance of focal masses, indicating that a sub-population of tumor cells in these cancers may be insensitive to current therapies and may be responsible for reinitiating tumor growth. This necessitates the development of newer drugs in the market that demonstrate greater efficacy in treating such aggressive cancers.

A global increase in neurological disorders has placed increased attention on cancers of the brain over the past decade. Neurological disorders are becoming one of the most prevalent types of disorders, due to longer life expectancy, greater exposure to infection and an increasingly sedentary lifestyle. Because few treatments for primary and metastatic cancers of the brain exist, costs are high and have acted as a restraint for the brain tumor therapeutics market.

Despite progress in surgery, radiotherapy and chemotherapeutic strategies, effective treatments for brain cancer are limited by a lack of specific therapies for the brain and the difficulty in transporting therapeutic compounds across the blood brain barrier. Therefore, there is a significant need for novel and effective therapeutic drugs and strategies that prolong survival and improve quality of life for brain tumor patients.

Several companies are making significant investments into R&D, which is expected to bring more treatment options to the market in the near future. Industry reports consistently project continued growth in the market.

One report estimates that the global brain tumor therapeutics market will reach a valuation of $2.74 billion in 2023, with the market expected to register a CAGR of 11% during the forecast period from 2018 to 2023. Another report projects that the global brain tumor therapeutics market will reach $3.4 billion by 2025, up from $2.25 billion in 2019 (https://nnw.fm/eDUjp).

Management Team

John M. Climaco is the CEO of CNS Pharmaceuticals. For 15 years, Climaco has served in leadership roles for a variety of health care companies. Recently, Climaco served as the Executive Vice President of Perma-Fix Medical S.A, where he managed the development of a novel method to produce Technitium-99. Climaco also served as President and CEO of Axial Biotech Inc., a DNA diagnostics company. In the process of taking Axial from inception to product development to commercialization, Climaco forged strategic partnerships with Medtronic, Johnson & Johnson and Smith & Nephew.

Christopher Downs, CPA, is the company’s Chief Financial Officer. Downs previously served as Interim Chief Financial Officer and Executive Vice President of InfuSystem Holdings Inc. (NYSE: INFU), a supplier of infusion services to oncologists in the United States. Downs holds a Bachelor of Science from the United States Military Academy at West Point, an MBA from Columbia Business School and a Master of Science in Accounting from the University of Houston-Clear Lake.

Dr. Donald Picker is the Chief Scientific Officer of CNS. Picker has over 35 years of drug development experience. Prior to joining CNS, Picker worked at Johnson Matthey, where he was responsible for the development of Carboplatin, one of the world’s leading cancer drugs, which was acquired by Bristol-Myers Squibb with annual sales of over $500 million. In addition, he oversaw the development of Satraplatin and Picoplatin, third-generation platinum drugs currently in late-stage clinical development.

Sandra L. Silberman, M.D., Ph.D., is the Chief Medical Officer of CNS Pharmaceuticals. Silberman is a hematologist/oncologist who earned her B.A., Sc.M. and Ph.D. from the Johns Hopkins University School of Arts and Sciences, School of Public Health and School of Medicine, respectively, and her M.D. from Cornell University Medical College. She then completed both a clinical fellowship in hematology/oncology and a research fellowship in tumor immunology at the Brigham & Women’s Hospital and the Dana Farber Cancer Institute in Boston, Massachusetts. Silberman has played key roles in the development of many drugs, including Gleevec(TM), for which she led the global clinical development at Novartis. Silberman advanced several original, proprietary compounds into Phases I through III during her work with leading biopharmaceutical companies, including Bristol-Myers Squibb, AstraZeneca, Imclone and Roche.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP), closed Wednesday's trading session at $2.75, up 4.1667%, on 106,707 volume. The average volume for the last 3 months is 45,315 and the stock's 52-week low/high is $2.0573/$34.7988.

Recent News

• CNS Pharmaceuticals Inc. (NASDAQ: CNSP) - Scientists Discover Brain Cells That Aid Brain Cancer Development
• Preclinical Study Reveals Promising Treatment for Glioblastoma
• Researchers Solve 50-Year-Old Challenge in Making Cancer Drug

NRx Pharmaceuticals Inc. (NASDAQ: NRXP)

The QualityStocks Daily Newsletter would like to spotlight NRx Pharmaceuticals Inc. (NASDAQ: NRXP).

NRx Pharmaceuticals (NASDAQ: NRXP) , a biopharmaceutical company focused on neuroplastic therapies for depression and PTSD, announced the formation of NRx Defense Systems Inc., a Florida-based research and development subsidiary dedicated to advancing combined neuroplastic treatments using D-cycloserine and transcranial magnetic stimulation supported by robotic-enabled neuronavigation. The subsidiary will be led by Dr. Dennis McBride, with support from Chief Medical Innovation Officer Dr. Joshua Brown, and aims to pursue non-dilutive government and institutional funding while developing deployable solutions for military and first responder use, including a prototype in partnership with Zeta Surgical Inc. expected to be unveiled at the Clinical TMS Society annual meeting in June 2026.

To view the full press release, visit https://ibn.fm/LmoQY

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders, with a particular emphasis on conditions characterized by acute suicidality. The company is leveraging its proprietary NMDA receptor modulation platform to address significant unmet medical needs in suicidal depression, bipolar depression, chronic pain, and post-traumatic stress disorder (PTSD).

With a commitment to advancing life-saving treatments, NRx is developing novel therapeutics aimed at providing safer and more effective alternatives to current treatment options. Its lead investigational drug, NRX-101, is positioned to be the first FDA-approved oral therapy for suicidal bipolar depression. Additionally, the company is working to bring NRX-100 (intravenous ketamine) to market as an approved treatment for acute suicidal depression, a condition for which existing treatments remain limited.

By integrating cutting-edge science with a patient-focused mission, NRx aims to transform the standard of care for individuals suffering from severe psychiatric and neurological conditions.

NRx has also established HOPE Therapeutics, a subsidiary focused on delivering interventional psychiatric care through a nationwide clinic network. HOPE Therapeutics aims to become the first coordinated system of care for suicidal depression and PTSD, combining ketamine, Transcranial Magnetic Stimulation (TMS), digital therapeutics, and other precision psychiatry tools in a supervised clinical environment.

NRx is headquartered in Wilmington, Delaware. HOPE is headquartered in Miami, Florida.

Product Portfolio

NRx Pharmaceuticals’ pipeline includes multiple late-stage therapeutic candidates targeting psychiatric and neurological disorders:

• NRX-100: A preservative free intravenous ketamine formulation under development for acute suicidal depression, backed by strong clinical trial data and Fast Track designation from the FDA.
• NRX-101: An oral therapy with a dual mechanism targeting NMDA and 5-HT2A receptors, designed for patients with suicidal treatment-resistant bipolar depression. The drug has received Breakthrough Therapy designation from the FDA.
• Expanded Research: The company is further evaluating NRX-101 as a potential non-opioid treatment for chronic pain and a therapy for complicated urinary tract infections.

NRx’s therapeutic pipeline is designed to address conditions with limited or no treatment options, with the potential to improve patient outcomes and expand the standard of care.

HOPE Therapeutics

HOPE Therapeutics, a wholly owned subsidiary of NRx Pharmaceuticals, is establishing a national network of psychiatrist-led clinics focused on suicidal depression and PTSD. Its care model integrates preservative-free ketamine, TMS, digital therapeutics, and supervised psychiatric support to deliver rapid, measurable outcomes.

The company is targeting more than 30 clinic acquisitions by year-end 2025. Recent agreements include the acquisition of Dura Medical and a letter of intent with Neurospa TMS, strengthening HOPE’s foundation in interventional psychiatry. In April, HOPE also secured a term sheet for strategic investment from a global medical device manufacturer.

With ketamine sales already underway under a 503B license, HOPE projects $100 million in annual revenue and profitability by year-end 2025. Positioned as a standalone care delivery company, HOPE offers NRx a potential future spinout opportunity to unlock additional shareholder value.

Market Opportunity

The need for innovative treatments in mental health and pain management is substantial. Suicide is a leading cause of death in the United States, claiming nearly 50,000 lives each year, with over 12 million adults seriously considering suicide annually, according to the CDC.

Suicidal depression, a distinct and life-threatening condition, affects approximately 3.5 million Americans. Despite this prevalence, the only approved intervention remains electroconvulsive therapy (ECT), a treatment with significant side effects and limited access. NRx aims to address this urgent gap with NRX-100, a preservative-free intravenous ketamine formulation being developed as the first FDA-approved treatment specifically for suicidal depression.

Additionally, approximately 7 million Americans suffer from bipolar depression, a condition where nearly half of patients will attempt suicide during their lifetime and one in five may die by suicide. NRX-101, NRx’s oral drug candidate, targets this critical unmet need as a potential first-in-class therapy specifically for bipolar depression.

Beyond mood disorders, chronic pain affects over 50 million individuals in the U.S., and PTSD impacts more than 12 million people—conditions for which few non-opioid, fast-acting treatments are available. By addressing these high-risk, underserved populations, NRx Pharmaceuticals is positioned to enter multiple billion-dollar markets and reshape the standard of care for severe psychiatric and neurological illnesses.

Leadership Team

Jonathan C. Javitt, Founder, Chairman & Chief Executive Officer or NRx, and Co-CEO of HOPE, brings four decades of experience in pharmaceutical and medical device development. He has led blockbuster drug and device programs at major companies, including Allergan, Merck, and Novartis, and has served as an advisor to four U.S. presidential administrations.

Michael Abrams, Chief Financial Officer, has nearly 30 years of experience in finance, having served in executive roles, including CFO positions at Arch Therapeutics and FitLife Brands. His expertise spans investment banking, corporate finance, and business strategy.

Rick Panicucci, Chief Technology Officer, has more than 25 years of leadership in pharmaceutical manufacturing and process development. He has held key positions at Novartis, WuXi AppTec, and other major companies, leading multiple approved New Drug Applications.

Matthew Duffy, Chief Business Officer, NRx, Co-CEO of HOPE, has over 35 years of experience in biotechnology business development and investment banking. He has held leadership roles at Pfizer, MedImmune, and several financial institutions, specializing in corporate strategy and partnerships.

NRx Pharmaceuticals Inc. (NASDAQ: NRXP), closed Wednesday's trading session at $2.52, up 0.8%, on 1,081,601 volume. The average volume for the last 3 months is 832,270 and the stock's 52-week low/high is $1.62/$3.84.

Recent News

• NRx Pharmaceuticals Inc. (NASDAQ: NRXP) - DefenseNewsBreaks - NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Forms NRx Defense Systems Subsidiary to Advance Neuroplastic Therapies for Military and Government Applications
• MissionIRNewsBreaks - NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Appoints First Chief Commercial Officer Ahead of Ketamine Launch
• PsychedelicNewsBreaks - NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Receives FDA Labeling Feedback for Preservative-Free Ketamine Application

Beeline Holdings Inc. (NASDAQ: BLNE)

The QualityStocks Daily Newsletter would like to spotlight Beeline Holdings Inc. (NASDAQ: BLNE).

Beeline Holdings (NASDAQ: BLNE) announced a strategic partnership with Structured Real Estate Group to integrate its Embedded Mortgage and Title solutions into SRG’s AI-driven real estate platform, enabling homebuyers to access personalized financing, evaluate total ownership costs and initiate the mortgage process within a single digital environment. The collaboration will support the development of approximately 2,000 smart homes in the Dallas-Fort Worth area over the next 36 months, combining advanced home technology, energy-efficient systems and integrated infrastructure with Beeline’s AI-powered assistant “Bob” to streamline the homebuying journey, reduce friction and deliver a more transparent, efficient path to homeownership while advancing Beeline’s broader strategy to scale its embedded platform and expand its partner network.

To view the full press release, visit https://ibn.fm/QhVu4

Beeline Holdings Inc. (NASDAQ: BLNE) is a technology-forward mortgage and title platform leveraging AI, automation, and intuitive user experiences to simplify home financing. Through wholly owned subsidiary Beeline Loans Inc., the company delivers fast and flexible loan solutions for both primary homebuyers and real estate investors. Beeline has built an end-to-end digital lending ecosystem designed to eliminate friction, reduce costs, and dramatically shorten closing timelines.

Since completing its October 2024 merger with Eastside Distilling, Beeline has solidified its position as a next generation fintech mortgage originator. Its core vision centers on digitizing the mortgage journey with tools like AI chatbot Bob, proprietary production engine Hive, and an expanding SaaS product suite. These innovations enable Beeline to close loans in just 14–21 days—less than half the industry average—while achieving a Net Promoter Score above 80, more than four times higher than the sector benchmark.

Beeline’s mission is to make home loans effortless by giving users instant access to rate quotes, approvals, and document uploads—all online, 24/7. Having surpassed $1 billion in cumulative loan originations and achieved 38% year-over-year growth, Beeline is scaling its platform across the U.S. mortgage and real estate investing landscape.

The company is headquartered in Providence, Rhode Island.

Products

Beeline operates a fully digital, AI-enabled loan origination and title ecosystem. Key features include:

• Bob 2.0 – The industry’s first AI mortgage agent, available 24/7/365 to quote rates and pre-approve borrowers; Bob has delivered 6x lead conversion and 8x full application volume compared to traditional loan officers.
• Hive – A task-based processing engine that replaces manual workflows with scalable automation, cutting loan closing times to as little as 14 days.
• BlinkQC – Beeline’s proprietary AI quality control platform that replaces costly third-party reviews.
• Beeline Title – A fully diversified title services unit supporting digital collateral transfer, remote closings, and investor-focused solutions.
• MagicBlocks – A customizable AI sales agent platform developed by Beeline and spun out into its own entity; Beeline retains equity and licensing rights, positioning it to benefit from future growth and deployment of the technology.

The company also provides Debt Service Coverage Ratio (DSCR), bank statement, and conventional mortgage products tailored to investors, including short-term rental operators. Strategic partnerships with Rabbu and Red Awning streamline property analysis, financing, and management within a single ecosystem.

Market Opportunity

The U.S. mortgage market is poised for growth in 2025, with total mortgage origination volume expected to increase by 28% to $2.3 trillion, up from $1.79 trillion in 2024. This projection includes a 13% rise in purchase originations to $1.46 trillion.

Within this expanding market, investor lending, particularly through DSCR loans, represents a rapidly growing segment. DSCR loans, which are underwritten based on the income generated by the property rather than the borrower’s personal income, are ideal for real estate investors, particularly those purchasing long-term or short-term rental properties. Beeline has strategically positioned itself in this niche, with over one-third of its volume derived from DSCR products. Through its affiliate referral network and integrations with platforms like Rabbu, the company is actively expanding its market reach in this high-margin category.

Non-agency mortgage issuance, which includes DSCR loans, is projected to reach $160 billion in 2025, a 16% increase from 2024.

Leadership Team

Nick Liuzza, Chief Executive Officer, co-founded Beeline Mortgage LLC in 2019 after selling Linear Title & Closing and Linear Settlement Services to Real Matters. He also previously built New Age Nurses into a national staffing firm. He currently serves as EVP of Real Matters (TSX: REAL).

Jess Kennedy, Chief Operating Officer, is a co-founder of Beeline with 15 years of legal and real estate experience. She previously served as General Counsel and Chief Compliance Officer at Beeline and held roles at Solidifi, LeClairRyan, and Edwards Wildman Palmer LLP, handling complex real estate finance and title transactions.

Chris Moe, Chief Financial Officer, joined Beeline in 2023 with over 40 years of finance and investment banking experience. He has held senior roles at Red Cat Holdings (NASDAQ: RCAT), IRIS Therapeutic Devices, and Yates Electrospace Corporation, bringing deep public company and defense sector expertise.

Beeline Holdings Inc. (NASDAQ: BLNE), closed Wednesday's trading session at $2.4, up 0.8403361%, on 1,077,896 volume. The average volume for the last 3 months is 590,317 and the stock's 52-week low/high is $0.6202/$4.65.

Recent News

• Beeline Holdings Inc. (NASDAQ: BLNE) - CryptoNewsBreaks - Beeline Holdings, Inc. (NASDAQ: BLNE) Partners With Structured Real Estate Group to Integrate Embedded Mortgage Platform Into AI-Driven Real Estate Ecosystem
• Beeline Holdings Inc. (NASDAQ: BLNE) Q4 Revenue Surge Portends 2026 Growth
• Beeline Holdings Inc. (NASDAQ: BLNE) Reports 127% Revenue Growth and Key Milestones Achieved in Q4 2025, Detailing Strategic Priorities for 2026

SPARC AI Inc. (CSE: SPAI) (OTCQB: SPAIF)

The QualityStocks Daily Newsletter would like to spotlight SPARC AI Inc. (CSE: SPAI) (OTCQB: SPAIF).

Disseminated on behalf of SPARC AI Inc. (CSE: SPAI) (OTCQB: SPAIF) and may include paid advertising.

SPARC AI (CSE: SPAI) (OTCQB: SPAIF) recently announced the appointment of Matt McCrann as CEO of its U.S. subsidiary, a move that signals a focused push into the world’s largest defense market. “McCrann previously served as CEO of the U.S. subsidiary of DroneShield, where he led operational expansion during a period of revenue growth and increasing federal adoption,” an article discussing this reads. “McCrann’s mandate is operational rather than symbolic. He will lead SPARC AI’s North American expansion, build out U.S. infrastructure and teams, advance field evaluations and pilot programs, and align with active procurement pathways. The focus is clear: convert technology into deployable capability across air, land, and maritime domains.”

To view the full article, visit https://ibn.fm/PFsFt

SPARC AI Inc. (CSE: SPAI) (OTCQB: SPAIF) develops next-generation, GPS-free target acquisition system and autonomous navigation software for drones and edge devices. Its zero-signature technology delivers real-time detection, tracking, and behavioral insights without reliance on radar, lidar, or heavy sensors. The company’s platform transforms unmanned systems into autonomous tools capable of identifying and engaging targets in GPS-denied environments.

The company’s vision is to redefine situational awareness by merging advanced mathematics, AI modeling, and edge computing into a unified intelligence architecture. SPARC AI aims to empower defense, rescue, and commercial organizations to operate safely and effectively in signal-contested environments where traditional navigation systems fail.

Its mission is to build the world’s most trusted geolocation intelligence platform that operates without GPS, enabling seamless interoperability across air, land, and sea devices.

SPARC AI is headquartered in Toronto, Canada.

Technology

SPARC AI’s technology suite delivers precision target acquisition, navigation, and autonomous intelligence in environments where GPS and traditional sensors fail. At its core is the Target Acquisition System, a software-only solution that determines the geolocation of any visible object using camera telemetry data. By removing the need for specialized hardware like lasers, radar, or lidar, the platform reduces weight, power use, and cost. Built on advanced mathematical modeling, it constructs a 3D understanding of terrain and position, achieving GPS-level accuracy in a zero-signature configuration suited for defense, rescue, and commercial operations.

SPARC AI Mobile extends this capability to handheld and field-issued devices, allowing operators to mark and transmit target coordinates directly from smartphones or rugged tablets. Once a target is identified, the device relays the coordinates to a connected drone, which autonomously navigates to the location for reconnaissance or engagement. The mobile system maintains accuracy even in GPS-jammed or degraded environments, turning each device into a connected node within a broader distributed network.

The company’s GPS-Denied Navigation engine enables mission planning and execution without satellite signals. Operators can design flight paths, define perimeters, and simulate routes to identify optimal vantage points and minimize resource use. Counter-surveillance and threat-prediction tools model adversarial visibility, helping users avoid detection and maximize ground coverage. Together, these capabilities form the foundation of SPARC AI’s software architecture, providing the intelligence backbone for its integrated command platform.

Overwatch Target Intelligence

Overwatch unifies all SPARC AI technologies, including its Target Acquisition, Mobile, and Navigation systems, into a single mission-ready platform that fuses detection, classification, tracking, and navigation in real time. It transforms drones and robotic systems into fully autonomous intelligence assets by synchronizing data across connected devices. The platform’s zero-signature design ensures complete operational security, allowing defense and rescue teams to conduct surveillance, reconnaissance, and engagement without GPS or active sensors.

Within Overwatch, the ATLAS Visibility Intelligence Engine enhances mission planning and reconnaissance through 2D and 3D visualization. Users can simulate line-of-sight coverage from any altitude, identify unseen or occluded areas, and optimize routes for surveillance or search and rescue. Operating entirely through software, ATLAS produces high-fidelity visibility data without mapping drones or additional power consumption, providing a lightweight, silent, and sensor-free alternative to lidar-based systems.

The SPARC AI SDK and open API framework extend Overwatch’s interoperability. Developers can embed SPARC AI’s intelligence into third-party systems such as PX4- and ArduPilot-powered drones, the world’s most widely used open-source flight platforms. The SDK provides REST APIs with bindings for Python, C++, and JavaScript and supports hardware including NVIDIA Jetson, Qualcomm Robotics RB5, and Raspberry Pi. Through these integrations, Overwatch serves as the command and intelligence layer of SPARC AI’s ecosystem, linking distributed drones, sensors, and edge devices into a coordinated autonomous network that operates entirely without GPS.

Market Opportunity

SPARC AI operates within the rapidly expanding defense, security, and commercial drone markets projected to exceed $100 billion over the next decade. The company’s software-defined approach addresses the global demand for autonomous systems capable of performing in denied, degraded, intermittent, and limited (DDIL) environments, positioning SPARC AI at the forefront of next-generation geolocation and targeting solutions.

Fortune Business Insights projects the global commercial drone market will reach approximately $65.25 billion by 2032, while Grand View Research estimates the combined drone hardware and services market will grow to $163.6 billion by 2030. With its per-device subscription model and integration across drones and robotic systems, SPARC AI is structured to capture recurring revenue from this accelerating adoption of GPS-denied intelligence technologies.

Leadership Team

Anoosh Manzoori, CEO, brings extensive experience as a technology entrepreneur, investor, and director, having founded, scaled, and exited multiple high-tech companies. He has taken five companies public, served on seven public company boards, and invested in innovations spanning cloud, fintech, biotech, IoT, defense, and AI.

Justin Hanka, Director, is an investment banking professional with 25 years of experience in mergers and acquisitions and capital markets. He has held executive roles at high-growth companies including iSelect.com.au and Helpmechoose, achieving multiple successful exits.

Anthony Haberfield, Director, is an international financial services executive with 30 years of experience across the Asia Pacific region, specializing in strategy, transformation, procurement, and emerging technology.

SPARC AI Inc. (OTCQB: SPAIF), closed Wednesday's trading session at $1.75, up 2.1004%, on 50,629 volume. The average volume for the last 3 months is 79,750 and the stock's 52-week low/high is $0.0792/$2.9.

Recent News

• SPARC AI Inc. (CSE: SPAI) (OTCQB: SPAIF) - TechMediaBreaks - SPARC AI Inc. (CSE: SPAI) (OTCQB: SPAIF) Targets Growth in Defense Sector with Strategic Appointment
• SPARC AI Inc. (CSE: SPAI) (OTCQB: SPAIF) Advances Ukraine Defense Initiatives as Electronic Warfare Reshapes Battlefield
• TechMediaBreaks - SPARC AI Inc. (CSE: SPAI) (OTCQB: SPAIF) (Frankfurt: 5OV0) Releases Updated Investor Presentation Highlighting Growth Strategy

LaFleur Minerals Inc. (CSE: LFLR) (OTCQB: LFLRF)

The QualityStocks Daily Newsletter would like to spotlight LaFleur Minerals Inc. (CSE: LFLR) (OTCQB: LFLRF).

This article has been disseminated on behalf of LaFleur Minerals and may include paid advertising.

LaFleur Minerals (CSE: LFLR) (OTCQB: LFLRF) (FSE: 3WK0) announced it has selected Trafigura Canada Limited to arrange and provide a prepayment financing facility of up to C$30 million along with a gold doré offtake agreement to support development of the Swanson Gold Deposit and operations at the Beacon Gold Mill in Québec, subject to definitive agreements and due diligence. The proposed facility, which includes no commodity hedging requirements and an initial tranche of up to C$15 million, is expected to fund ramp-up toward 1,250 tonnes per day processing capacity while providing a pathway for future expansion to 3,000–4,000 tpd, as the company advances toward a targeted first gold pour in the second quarter of 2026.

To view the full press release, visit https://ibn.fm/hiCsw

LaFleur Minerals Inc. (CSE: LFLR) (OTCQB: LFLRF) is a Canadian exploration and development company advancing the district-scale Swanson Gold Project in Québec’s prolific Abitibi Gold Belt and progressing toward the near-term restart of gold production at its wholly owned Beacon Gold Mill. The company’s strategy centers on consolidating strategic land packages—highlighted by its flagship Swanson Gold Project, a 160 km² district-scale property that includes several prospects rich in gold and critical metals previously held by Monarch Mining, Abcourt Mines, and Globex Mining. The company is leveraging its 100%-owned, fully permitted and recently refurbished Beacon Gold Mill to transition from explorer to near-term gold producer—a key inflection point that typically triggers a market re-rating, further bolstered by current rising gold market prices. By processing material from Swanson and offering custom milling to regional projects, LaFleur aims to generate cash flow with minimal capital outlay, targeting annual gold production of up to 15,000 to 20,000 ounces by early 2026.

LaFleur’s vision is to evolve into an intermediate gold producer by capitalizing on strong market conditions and Québec’s rich mining infrastructure. The location, in the world-class Abitibi Gold Belt, and its infrastructure advantage, positions LaFleur for regional consolidation, strategic partnerships, or acquisition interest. Its mission emphasizes efficient value creation through methodical exploration, low-cost asset advancement, and opportunistic acquisitions—including land and deposits from Monarch Mining, Abcourt Mines, and Globex Mining.

Québec ranks among the world’s top mining jurisdictions, offering access to flow-through capital and regulatory stability. LaFleur’s integrated strategy—combining exploration at Swanson, a permitted mill at Beacon, and potential custom milling agreements—supports a streamlined path to near-term production.

LaFleur Minerals is headquartered in Vancouver, British Columbia.

Projects

LaFleur Minerals’ operations focus on two strategically located assets in the Abitibi Gold Belt: the Swanson Gold Project and the Beacon Gold Mill and Mine. These projects leverage the region’s world-class mining infrastructure and high-grade gold potential to drive the company’s transition to production.

Swanson Gold Project

The Swanson Gold Project spans 16,600 hectares and hosts the Swanson, Bartec, and Jolin gold deposits along a major structural break in the Abitibi Gold Belt. The 2024 Mineral Resource Estimate for the Swanson deposit outlines 123,400 oz of gold in Indicated category (2.1 million tonnes at 1.8 g/t) and 64,500 oz in Inferred category (872,000 tonnes at 2.3 g/t). Located 66 km north of Val-d’Or, the Project is accessible by road and rail and benefits from more than 36,000 meters of historical drilling, along with existing infrastructure including an 80-meter decline portal.

Recent work—including airborne magnetics, soil sampling, and Induced Polarization surveys—has identified multiple high-priority targets and resulted in several high-grade gold assay results, including a grab sample grading 11.71 g/t Au at Jolin, which points to significant upside as the Company prepares to test multiple new zones.

LaFleur has defined over 50 drill targets at Swanson and nearby prospects (Bartec, Jolin, Marimac) and is completing a minimum 5,000-metre diamond drilling beginning in June 2025. LaFleur Minerals has also initiated permitting for a 100,000-tonne surface bulk sample averaging 1.89 g/t Au, which it plans to process at the Beacon Gold Mill as part of a near-term production strategy.

Beacon Gold Mill

LaFleur’s 100%-owned Beacon Gold Mill is a fully refurbished and permitted mill and tailings storage facility capable of processing 750 tonnes per day (tpd), with potential expansion to 1,800 tpd, with access to numerous nearby gold deposits that could be prime sources of ore. Located only 60 km from Swanson, it underwent a $20 million upgrade by Monarch Mining in 2022 and has been under care and maintenance since early 2023. LaFleur is finalizing a C$5-6 million restart plan, ramping up production by late 2025 into early 2026, processing Swanson mineralized material and assessing custom milling opportunities for regional deposits, creating multiple potential revenue streams.

The Beacon Gold Mill is a de-risked, proven asset that benefits from existing infrastructure, including access to roads, power, and skilled labor, and further enhances the overall value proposition of LaFleur by providing a clear path to production and potential revenue-generation.

Market Opportunity

LaFleur Minerals is targeting the gold mining and processing market in Québec’s Abitibi Gold Belt, one of the world’s most productive gold regions. Its fully permitted Beacon Gold Mill, with a 750 tpd capacity and authorization to process 1.8 million tonnes of tailings, is strategically positioned to handle material from LaFleur’s Swanson Gold Project and to offer custom milling for nearby deposits such as Granada Gold. The company projects annual production of over 30,000 ounces of gold once in full production, with potential for significant revenue generation based on prevailing market prices.

Global demand for gold remains robust, driven by geopolitical risk, inflation hedging, and central bank accumulation. The World Gold Council forecasts 3-5% annual demand growth through 2030, with average prices expected between $3,200 and $3,500/oz. Within this environment, Québec’s top-tier mining jurisdiction—ranked fifth globally by the Fraser Institute in 2023—offers streamlined permitting and access to flow-through capital. LaFleur’s low-cost Beacon restart (C$5-6 million) and proximity to more than 100 active and historical mines position the company to fill a growing need for small-to-medium scale custom milling.

At Swanson, LaFleur plans to grow its current 187,900-ounce resource toward 1 million ounces through its 2025 drilling program. This hub-and-spoke strategy, leveraging centralized milling and strong local infrastructure, reduces development risk and strengthens LaFleur’s foothold in one of the most attractive gold belts in the world.

Leadership Team

Kal Malhi, Chairman, is a successful entrepreneur and the Founder of Bullrun Capital Inc., where he has raised over $300 million for early-stage companies across the mining, oil and gas, biomedical, agriculture, and technology sectors. He specializes in advancing academic research into commercial ventures and public listings, with more than two decades of capital markets and leadership experience.

Paul Ténière, M.Sc., P.Geo., Chief Executive Officer, is a seasoned mining executive and Professional Geologist with over 25 years of global experience in the development of precious and base metals, critical minerals, and metallurgical coal projects. Mr. Ténière is an expert in NI 43-101 and S-K 1300 disclosure standards and has held senior roles including President & CEO, SVP Exploration, and Director with several publicly traded mining companies. Mr. Ténière also worked at the Toronto Stock Exchange (TSX) and TSX Venture Exchange as a mining expert and Senior Listings Manager listing dozens of mining companies and ensuring listed issuers met their corporate governance and compliance and disclosure requirements.

Harry Nijjar, Chief Financial Officer and Corporate Secretary, serves as Managing Director at Malaspina Consultants Inc., providing CFO and strategic financial advisory services to companies across multiple industries. He holds a CPA CMA designation from the Chartered Professional Accountants of British Columbia and a Bachelor of Commerce from the University of British Columbia.

Louis Martin, P.Geo., Technical Advisor and Exploration Manager, is a veteran geologist with more than 40 years of exploration experience. He has played key roles in significant gold and base metal discoveries, including the Louvicourt (1989) and West Ansil (2005) deposits—both recognized by the Association de l’Exploration Minière du Québec (AEMQ). He previously served as VP Exploration at Clifton Star Resources, where he led the pre-feasibility study for the 4.5 million-ounce Duparquet Gold Project. He is a registered geologist in Québec and Ontario.

Tara Asfour, Corporate Communications, Investor Relations and Strategy, is an experienced executive consultant with over 12 years of management, investor relations, communications and marketing experience, specialized in capital markets. In her previous positions, Ms. Asfour has led over US$550 million worth of fundraising and strategic development initiatives. Ms. Asfour holds a Master’s degree in Business Management, a Financial Markets Certificate from Yale University, and a Certificate in Alternative Investments from HBS. Previous positions include investor relations executive at Red Pine Exploration, Fancamp Exploration, Communications Director at Dominion Water Reserves (now Prime Drink Group Corp) and advisor to various other publicly listed firms in the resource and technology sectors. Ms. Asfour holds the Institute for Governance (IGOPP) Certification in Governance, Ethics in Business Environment and Corruption Prevention.

Peter Espig, Strategic Advisor and Consultant, has served as Vice-President at Goldman Sachs Japan in both the Principal Finance and Securitization Group and the Asia Special Situations Group, where his team participated in more than $10 billion in structured deals, capital raises, and cross-border transactions. Prior to Goldman Sachs, he was Vice-President at Olympus Capital, a New York-based private equity firm, where he focused on corporate restructurings, investment analysis, and international financing negotiations. He also played a pioneering role in some of the earliest SPAC transactions, totaling over US$1.2 billion, and brings deep experience in disciplined capital deployment and turnaround execution. Since 2013, Mr. Espig has served as President and CEO of Nicola Mining Inc. and is a board member of ESGold Corp and First Lithium Minerals. Mr. Espig holds a Bachelor of Arts from the University of British Columbia and an MBA from Columbia Business School, where he was a Chazen International Scholar. He has served on various public boards and was recognized among Industry Era’s “Top 10 Admired Leaders” in 2023.

Jean Lafleur, Senior Technical Advisor, is a Professional Geologist (Québec) with 45 years of experience in Canada and internationally including USA, Mexico, Latin America, Ireland, Spain and Africa. Earlier in his career he worked with Newmont, Falconbridge, Dome Mines, and Placer Dome and has been a C-suite executive for a number of junior exploration companies. Jean has remained active as a technical, management, and financing consultant with junior explorers since the early 2000’s through his own geological consultancy firm and throughout his career has led a number of teams in the discovery of precious and base metals, nickel, PGE’s, uranium, and iron deposits. Jean’s expertise includes mining company and project evaluations, audits, technical reporting, exploration program planning and execution, and research and development with a strong focus on Québec. Jean currently acts as a Senior Consultant, North America for Appian Capital Advisory LLP, a mining-focused private equity firm based in London, UK where through his extensive professional network he sources and presents potential mining transactions in North America to the Appian team for investment opportunities.

LaFleur Minerals Inc. (OTCQB: LFLRF), closed Wednesday's trading session at $0.4411, up 5.0238%, on 54,205 volume. The average volume for the last 3 months is 83,800 and the stock's 52-week low/high is $0.0631/$0.62.

Recent News

• LaFleur Minerals Inc. (CSE: LFLR) (OTCQB: LFLRF) - MiningNewsBreaks - LaFleur Minerals Inc. (CSE: LFLR) (OTCQB: LFLRF) (FSE: 3WK0) Secures Up to C$30 Million Prepayment Facility and Offtake Agreement With Trafigura
• LaFleur Minerals Inc. (CSE: LFLR) (OTCQB: LFLRF) Nears Restart of Gold Production this Quarter with First Gold Pour on the Horizon
• LaFleur Minerals Inc. (CSE: LFLR) (OTCQB: LFLRF) Bolsters Report on Positive PEA, Nears Gold Production

Earth Science Tech Inc. (OTC: ETST)

The QualityStocks Daily Newsletter would like to spotlight Earth Science Tech Inc. (OTC: ETST).

Earth Science Tech (OTC: ETST) , a strategic holding company, was featured in a recent article that discussed its strives to build value by acquiring and actively managing businesses. The publication reads, “Earth Science Tech takes an approach that prioritizes capital discipline, execution, and long-term value creation across the platforms it operates, while focusing on scaling businesses that can grow sustainably and increase shareholder value. The wholly owned and majority-owned subsidies that the company operates include: Mister Meds LLC: A compounding pharmacy that delivers personalized wellness plans and dedicated support to patients across the USA… RxCompoundStore.com LLC: Another compounding pharmacy that’s authorized to fulfill prescriptions across over 20 states and Puerto Rico… Peaks Curative LLC: A company and telemedicine referral platform that provides doctor-verified telehealth treatments… Las Villas Health Care Inc.: A healthcare provider that serves the Spanish-speaking community and offers personalized wellness programs… DOConsultations LLC: A telehealth platform that offers personalized health wellness programs and supports direct delivery through the company’s partner pharmacies… Earth Science Foundation Inc.: A nonprofit organization that acts as the charitable arm of the company and provides qualified individuals with financial assistance related to prescription costs.”

To view the full article, visit https://nnw.fm/iaHMy

Earth Science Tech Inc. (OTC: ETST) is a strategic holding company that builds value by acquiring and actively managing operating businesses in pharmaceuticals, telemedicine, healthcare services, real estate, and select consumer markets. The company focuses on controlling interests in subsidiaries where operational oversight, regulatory compliance, and disciplined scaling can drive durable growth.

Since 2022, Earth Science Tech has completed a deliberate transition away from legacy activities and repositioned the organization around healthcare and pharmaceutical operations. That shift has been supported by regulatory alignment, expanding operating capabilities, and the assembly of a diversified portfolio of revenue-generating businesses.

Today, the company’s approach emphasizes execution, capital discipline, and long-term value creation across its operating platforms, with a focus on scaling businesses that can grow sustainably while enhancing shareholder value.

The company is headquartered in Miami, Florida.

Subsidiaries

Earth Science Tech conducts its operations through a portfolio of wholly owned and majority-owned subsidiaries spanning pharmaceutical compounding, telemedicine, healthcare services, real estate development, and direct-to-consumer products.

• RxCompoundStore.com LLC – A fully licensed compounding pharmacy based in Miami, Florida, authorized to fulfill prescriptions across more than 20 U.S. states and Puerto Rico, with ongoing licensure expansion efforts nationwide.
• Mister Meds LLC – A Texas-based compounding pharmacy operating from a 5,000-square-foot facility with advanced sterile and hazardous drug compounding capabilities, acquired to expand production capacity and geographic reach.
• Peaks Curative LLC – A telemedicine referral platform providing asynchronous consultations for Peaks-branded compounded medications, supported by an expanding provider network and recent entry into the veterinary market through Zoolzy.com.
• DOConsultations LLC – An online telehealth platform focused on customized medication formulations, supporting direct-to-patient delivery through partner pharmacies.
• Las Villas Health Care Inc. – A brick-and-mortar and telehealth healthcare provider serving the Spanish-speaking community, offering specialized wellness and sexual health services.
• Avenvi LLC – A diversified real estate development and asset management company overseeing property investments, development projects, and the company’s ongoing share repurchase program.
• MagneChef (80% interest) – A direct-to-consumer retail brand leveraging proprietary intellectual property to develop and market kitchen and cooking-related products, with recent expansion into premium American-made BBQ tools.
• Earth Science Foundation Inc. – A 501(c)(3) nonprofit organization serving as the company’s charitable arm, providing financial assistance for prescription costs to qualified individuals.

Collectively, these subsidiaries provide Earth Science Tech with diversified exposure across regulated healthcare services, digital health platforms, real estate assets, and proprietary consumer brands.

Market Opportunity

Earth Science Tech is primarily positioned within the pharmaceutical compounding and telemedicine markets, both of which are experiencing sustained growth driven by demand for personalized healthcare solutions, expanded access to care, and increasing adoption of remote service models.

The pharmaceutical compounding market continues to benefit from rising demand for customized medications, improved patient adherence, and supply-chain flexibility. According to Grand View Research, the global compounding pharmacies market was valued at approximately $13.1 billion in 2023 and is projected to reach $18.6 billion by 2030, representing a compound annual growth rate of 5.11% from 2024 to 2030. Earth Science Tech’s compounding operations through RxCompoundStore.com and Mister Meds align directly with this expanding market segment.

Telemedicine represents a second core growth vertical for the company, supporting the clinical delivery of pharmaceutical products and healthcare services. According to Fortune Business Insights, the global telemedicine market was valued at $111.99 billion in 2025 and is projected to grow to $532.08 billion by 2034, reflecting a compound annual growth rate of 20.0%, with North America accounting for approximately 48% of market share in 2025. Platforms operated by Peaks Curative and DOConsultations participate directly in this rapidly expanding digital health ecosystem.

Additional exposure to specialty healthcare clinics and real estate development provides diversification alongside the company’s core pharmaceutical and telemedicine operations.

Leadership Team

Giorgio R. Saumat, Chief Executive Officer and Chairman of the Board, is an investor and entrepreneur with more than 20 years of experience investing in, operating, and advising private businesses, including founding CASAU Group, a private equity firm focused on real estate, and POINT96 Consulting, which provides strategic planning services to businesses and accredited investors.

Ernesto L. Flores, Chief Financial Officer, is a financial executive with over a decade of experience in accounting, taxation, and financial management, having held senior roles overseeing compliance and financial operations at logistics and investment firms.

Mario G. Tabraue, President and Chief Operating Officer, brings experience across real estate, maritime operations, and digital infrastructure and was instrumental in acquiring RxCompoundStore.com with the vision of scaling it into a nationally competitive pharmaceutical and telemedicine platform.

Christopher Rose, Chief Technology Officer, is a technology and automation executive who previously led enterprise-wide automation initiatives at a Fortune 100 company, delivering large-scale operational efficiencies and global process automation.

Earth Science Tech Inc. (OTC: ETST), closed Wednesday's trading session at $0.1288, up 8.2353%, on 119,193 volume. The average volume for the last 3 months is 102,970 and the stock's 52-week low/high is $0.001/$0.237.

Recent News

• Earth Science Tech Inc. (OTC: ETST) - NetworkNewsBreaks - Earth Science Tech Inc. (ETST) Advancing Multi-Platform Healthcare Strategy
• Earth Science Tech Inc. (ETST) Builds Integrated Healthcare Platform for Scalable Growth
• BioMedNewsBreaks - Earth Science Tech, Inc. (OTC: ETST) Launches MyOnlineConsultation Platform Through MOCTeledoc

Frontieras North America Inc.

The QualityStocks Daily Newsletter would like to spotlight Frontieras North America Inc.

• Frontieras notes milestone moment: groundbreaking of facility based on a new industrial model built on extracting the full value of coal.
• The company’s proprietary approach reframes coal as a versatile raw material capable of producing a wide spectrum of outputs through controlled processing.
• At the core of this strategy is Frontieras’s FASForm(TM) process, a solid carbon fractionation technology that separates coal into its constituent components.

Recent geopolitical conflict and supply disruptions have underscored how vulnerable global energy systems remain, with oil markets particularly exposed to shocks that can ripple through economies and industries almost instantly. The current situation has renewed the urgency of finding new approaches to domestic, feedstock-driven energy production are gaining urgency. Frontieras North America is advancing one such model through its proprietary technology that transforms coal into fuels, hydrogen and industrial products, positioning the resource as a strategic alternative in a constrained energy environment.

Frontieras North America Inc. is an energy and environmental technology company focused on redefining how coal and other solid hydrocarbons are utilized within modern energy and industrial systems. Rather than treating coal as a fuel to be burned, the company applies patented processing technology to reform solid hydrocarbons into multiple market-ready energy and industrial products designed for existing global markets.

The company’s approach is rooted in extracting greater value from abundant natural resources through industrial innovation, addressing inefficiencies historically associated with conventional coal use. By separating coal into gases, liquids, and purified solid carbon, Frontieras positions coal as a versatile feedstock capable of supporting transportation, manufacturing, agriculture, and industrial infrastructure demand.

Frontieras emphasizes closed-loop, zero-waste processing as a means of producing energy products more efficiently while reducing emissions and unused byproducts.

Products and Projects

Frontieras’ core platform is FASForm™, a patented Solid Carbon Fractionation process that deconstructs coal by extracting volatiles, moisture, and contaminants. The process produces hydrogen, methane, naphtha, diesel, aviation fuel, and FASCarbon™, a low-sulfur technical carbon product.

The company is developing its first commercial-scale FASForm™ facility in Mason County, West Virginia, an estimated $850 million project designed to process approximately 7,500 tons of coal per day, or about 2.7 million tons annually. The facility is supported by a 10-year feedstock MOU using Pittsburgh #8 coal and a 10-year offtake LOI covering 100% of produced fuels, FASCarbon™, sulfuric acid, and fertilizer.

Engineering, construction, operations, logistics, and insurance partners are under executed agreements, and the project has completed FEL 1 and FEL 2, with substantial FEL 3 underway. Following its initial Mason County development, Frontieras plans to deploy additional FASForm™ facilities in West Virginia, Texas, and Wyoming, with longer-term international deployment in markets where its patent portfolio is in force.

Market Opportunity

Frontieras targets established global energy and chemicals markets with a combined estimated value exceeding $2.1 trillion. The company’s product portfolio aligns with large, existing demand across diesel, hydrogen, naphtha, jet fuel, technical carbon – coke, industrial chemicals, and fertilizer markets. These products are core industrial inputs with long-established supply chains, entrenched end-use applications, and global pricing benchmarks, reducing reliance on the creation of new or speculative markets.

These markets serve essential roles across transportation, agriculture, industrial machinery, aviation, steel manufacturing, petrochemicals, and food production, supporting continuous demand driven by infrastructure, manufacturing, and population growth. The planned design capacity of the first FASForm™ facility is approximately 7,500 tons per day, or about 2.7 million tons annually — equivalent to roughly 0.5% of current U.S. coal production. This design framework is intended to enable Frontieras to scale output incrementally while remaining aligned with existing market capacity, logistics networks, and demand profiles.

Leadership Team

Matthew McKean, Co-Founder & Chief Executive Officer, leads Frontieras’ overall strategy and execution and brings more than 25 years of experience across finance, operations, and business leadership. He previously co-founded a mortgage banking firm that grew into one of the largest originators in the southwestern U.S. before a successful exit, followed by senior leadership roles within large real estate finance organizations. McKean has been an active member of the CEO mentoring organization Vistage, advising companies across construction, finance, infrastructure, and consumer sectors. He holds a Bachelor of Science in Human Nutrition with an emphasis in Chemistry from Arizona State University and completed pre-med coursework.

Josephe Witherspoon, P.E., Co-Founder & Chief Technology Officer, is the inventor of the FASForm™ process and the author of the company’s core patents. He brings extensive experience in petroleum refining, natural gas processing, and chemical engineering from senior roles at Chevron, Enterprise Products, Sinclair Oil, and Marathon Petroleum. As a Process Design Engineer and Major Capital Project Manager, Witherspoon has led projects delivering significant operational and economic improvements. He holds a Bachelor of Science in Chemical and Fuels Engineering from the University of Utah and is a licensed Professional Engineer.

Andrea Moran, Chief Commercial Officer, oversees Frontieras’ commercialization strategy, capital formation, and go-to-market execution. She brings more than 25 years of experience in operations, management, and business development across the energy and infrastructure sectors. Prior to Frontieras, Moran served as Co-Founder and Vice President of Business Development at Yield Power Group, a project finance firm supporting energy and infrastructure projects ranging from $100 million to over $1 billion. She holds a Bachelor of Science in Political Science from the University of Wisconsin and serves on philanthropic and advisory boards.

José López, Chief Financial Officer, leads Frontieras’ financial strategy, operations, and capital planning. He brings over 20 years of experience in global finance and accounting, including senior roles at multinational public companies. López began his career at PwC’s external assurance practice, working across Houston, London, and The Hague. His background includes SEC reporting, corporate governance, FP&A, mergers and acquisitions, and capital markets transactions. He holds a Bachelor of Science in Accounting and Finance from the University of Houston–Clear Lake and is a licensed Certified Public Accountant.

Recent News

• Frontieras North America Inc. - Frontieras North America Inc. Launches New Era for Full Coal Utilization
• Frontieras North America Inc. Unlocks Value in America’s Energy Future
• InvestorNewsBreaks – Frontieras North America CEO Matthew T. McKean Frames Mason County Groundbreaking as Launch of New U.S. Energy Industry

Soligenix Inc. (NASDAQ: SNGX)

The QualityStocks Daily Newsletter would like to spotlight Soligenix Inc. (NASDAQ: SNGX).

• A recent Zacks Small-Cap Research report outlines a number of key milestones that position Soligenix for a potentially eventful period ahead.
• One of the most notable elements highlighted in the analysis is the strength of the interim data trends observed thus far in the FLASH2 study.
• Beyond the phase 3 program, the report highlights additional clinical and scientific developments that contribute to the depth of Soligenix’s pipeline.

Independent research coverage can play a meaningful role in shaping how emerging biotechnology companies are evaluated, particularly when it brings together clinical progress, financial positioning and forward-looking milestones into a cohesive outlook. A recent analysis from Zacks Small-Cap Research provides that perspective for Soligenix (NASDAQ: SNGX) , offering a detailed review of the company’s pipeline, upcoming catalysts and valuation potential while reinforcing the credibility of its development strategy.

Soligenix Inc. (NASDAQ: SNGX) is a late-stage biopharmaceutical company focused on developing and commercializing treatments for rare diseases with high unmet medical needs. Operating through two key segments, the company’s Specialized BioTherapeutics division is dedicated to oncology and inflammation therapies, while its Public Health Solutions segment advances vaccines and therapeutics targeting biothreats and infectious diseases.

The company is actively advancing multiple late-stage clinical programs, including HyBryte™ (SGX301), a novel photodynamic therapy for cutaneous T-cell lymphoma (CTCL). Additional candidates in development target psoriasis (SGX302), oral mucositis (SGX942), and Behçet’s disease (SGX945), while its public health efforts focus on heat-stable vaccines for ricin poisoning (RiVax®), Ebola (SuVax™), and Marburg (MarVax™) viruses, that have been supported by non-dilutive government grants and contracts of approximately $60 million to date.

With a diversified pipeline, multiple orphan and fast-track designations, and collaborations with government agencies, Soligenix is uniquely positioned for potential regulatory approvals and commercialization.

The company is headquartered in Princeton, New Jersey.

Pipeline and Development Programs

Specialized BioTherapeutics

Soligenix’s Specialized BioTherapeutics division develops treatments for oncology and inflammatory diseases, focusing on conditions with few or no effective therapeutic options. HyBryte™ (synthetic hypericin) has completed a Phase 3 study for CTCL, demonstrating statistically significant efficacy, and a second confirmatory Phase 3 trial is actively enrolling patients to support potential regulatory submissions worldwide. If approved, it would be the first non-mutagenic photodynamic therapy for early-stage CTCL, addressing an unmet medical need. It has received orphan drug designations in the U.S. and Europe, as well as Fast Track designation in the U.S.

SGX302, a photodynamic therapy based on the same active ingredient as HyBryte™, is in clinical development for mild-to-moderate psoriasis, with positive Phase 1/2 proof-of-concept results, it is actively enrolling patients in a Phase 2a clinical trial.

SGX942, designed to reduce inflammation and tissue damage in oral mucositis associated with cancer treatment, is progressing as a potential first-in-class therapy.
SGX945, targeting aphthous ulcers in Behçet’s disease, is actively enrolling in a Phase 2a clinical trial and has received fast-track designation, highlighting the urgency of developing effective treatments for this rare inflammatory condition.

Public Health Solutions

The company’s Public Health Solutions segment focuses on medical countermeasures for biothreats and emerging infectious diseases, leveraging non-dilutive government funding to advance its programs. RiVax®, a ricin toxin vaccine, has demonstrated strong preclinical and early clinical results and may be eligible for government procurement under the Strategic National Stockpile initiative.

The company’s RiVax®, as well as its vaccine candidates for Ebola and Marburg viruses are based on its proprietary ThermoVax® technology, which stabilizes vaccines for long-term storage without refrigeration. This approach could be transformative in regions where maintaining cold-chain logistics is challenging.

The ongoing development of these vaccines is supported by funding from NIH, BARDA, and DTRA, with the potential for up to three priority review vouchers (PRVs) upon regulatory approval, to be used for future programs or sold. Notably, PRVs have previously sold for roughly $100 million.

Market Opportunity

Soligenix targets markets with significant commercial potential, focusing on rare diseases and biodefense applications. HyBryte™ addresses CTCL, a disease affecting over 68,000 patients across the U.S. and Europe, with a total market opportunity exceeding $250 million. SGX302, the company’s therapy for mild-to-moderate psoriasis, serves a much larger population, as over eight million people in the U.S. are affected by the condition, representing a global market opportunity exceeding $1 billion.

SGX942, developed for oral mucositis in head and neck cancer patients, is aimed at a market worth more than $500 million, while SGX945 for Behçet’s disease serves a niche segment valued at over $200 million worldwide.

In addition to its rare disease programs, Soligenix’s Public Health Solutions division has the potential to generate significant revenue through government procurement contracts. By focusing on both orphan drug markets and government-funded biodefense initiatives, Soligenix has positioned itself for sustained revenue growth through multiple high-value opportunities.

Leadership Team

Christopher J. Schaber, PhD, Chairman, President & CEO, brings to the company more than 35 years of experience in the biopharmaceutical industry. Before joining Soligenix, he held senior and operational leadership roles at Discovery Laboratories, Acute Therapeutics, Ohmeda Pharmaceuticals, The Liposome Company, and Wyeth Ayerst Laboratories. He has extensive expertise in drug development, regulatory affairs, and corporate strategy, positioning him to drive Soligenix’s growth and advancement toward commercialization.

Richard Straube, MD, Chief Medical Officer, has more than 35 years of experience in drug development and clinical research. Prior to joining Soligenix, he held key leadership roles at Stealth Peptides, INO Therapeutics, Ohmeda Pharmaceuticals, and Centocor. Throughout his career, he has played a crucial role in bringing innovative therapies to market, particularly in inflammatory diseases and immunology, making him a valuable asset in advancing Soligenix’s late-stage clinical programs.

Oreola Donini, PhD, Chief Scientific Officer, has more than 20 years of experience in pharmaceutical research and development, with expertise in immunology, inflammation, and rare diseases. Before joining Soligenix, she held leadership positions at Inimex Pharmaceuticals, ESSA Pharma, and Kinetek Pharmaceuticals, where she worked on novel drug discovery and translational medicine. Her experience in preclinical research and product development supports Soligenix’s continued innovation in biopharmaceuticals.

Jonathan Guarino, CPA, CGMA, Chief Financial Officer, has over 25 years of experience in corporate finance and strategic financial planning. Before joining Soligenix, he held financial leadership positions at Hepion Pharmaceuticals, Covance, BlackRock, and Barnes & Noble. His expertise in financial management, accounting, and capital markets plays a critical role in Soligenix’s financial strategy and operational efficiency.

Soligenix Inc. (NASDAQ: SNGX), closed Wednesday's trading session at $1.15, even for the day, on 182,532 volume. The average volume for the last 3 months is 314,270 and the stock's 52-week low/high is $1/$6.2299.

Recent News

• Soligenix Inc. (NASDAQ: SNGX) - Soligenix Inc. (NASDAQ: SNGX) Gains Analytical Validation as Pipeline Progress Drives Forward Outlook
• MissionIRNewsBreaks - Soligenix Inc. (NASDAQ: SNGX) Showcased for Smarter Path to Drug Development
• BioMedNewsBreaks - Soligenix Inc. (NASDAQ: SNGX) Publishes Positive HyBryte Study Results In Oncology and Therapy

MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF)

The QualityStocks Daily Newsletter would like to spotlight MindBio Therapeutics Corp. (OTCQB: MBQIF).

Disseminated on behalf of MindBio Therapeutics Corp., may include paid advertisements.

This article has been disseminated on behalf of MindBio Therapeutics Corp. and may include paid advertising.

MindBio Therapeutics (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF) , a biotechnology company focused on AI-driven voice analytics for drug and alcohol intoxication detection, announced it has appointed Venture Liquidity Providers (VLP), subject to regulatory and final approvals, to provide market-making services aimed at maintaining an orderly trading market for its common shares. The service will be conducted through W.D. Latimer Co. Ltd. in compliance with Canadian Securities Exchange policies, with MindBio agreeing to pay $5,000 per month over a 12-month term, which may be terminated at any time, while both parties operate at arm’s length and VLP holds no direct or indirect interest in the company or its securities.

To view the full press release, visit https://ibn.fm/4evlA

MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) is a biotechnology company developing and commercializing artificial intelligence-powered health prediction technologies that use the human voice as a diagnostic input. The company’s platform is centered on acoustic biomarker analysis, transforming speech into measurable physiological insights that can be used to detect drug and alcohol intoxication and support broader health monitoring applications. By leveraging voice as a non-invasive data source, MindBio is advancing a scalable approach to real-time diagnostics.

The company’s technology is built on clinical trials and large-scale data analysis, with predictive models trained on more than 50 million data points and supported by multiple studies demonstrating high levels of accuracy in intoxication detection. This foundation enables both consumer-facing and enterprise-grade applications, positioning MindBio to address use cases ranging from personal awareness tools to workforce safety and regulatory compliance in high-risk industries.

MindBio is advancing toward commercialization through a dual-channel strategy that includes a launched consumer application and enterprise solutions in development for large-scale deployment. Recent company activity highlights a transition toward field implementation, particularly within the mining sector, alongside expansion into industries such as aviation and construction. The platform is also being developed for broader applications in telehealth and remote monitoring.

The company is headquartered in Melbourne, Australia.

Products and Platform

Booze AI (Consumer Application)

MindBio’s Booze AI application enables users to estimate blood alcohol concentration using voice input via a smartphone or web-based interface. The platform combines speech analysis with behavioral tasks to provide real-time insights into intoxication levels and performance impairment, supporting awareness and harm prevention through accessible, non-invasive testing.

Enterprise Solutions

MindBio is developing enterprise-grade solutions for safety-critical industries such as mining, aviation, and construction, where impairment detection is essential. These solutions are designed for scalable, real-time screening of drug and alcohol intoxication, addressing limitations of traditional methods that are invasive, time-consuming, and operationally restrictive at scale. Recent developments include expansion into South America, deployment of engineering teams, and preparation for initial field testing of enterprise solutions in mining environments.

Core Technology and Platform

The company’s platform is built on proprietary AI models trained on more than 50 million data points and over 140 acoustic parameters extracted from human speech. This acoustic biomarker engine enables rapid, non-invasive detection of physiological and cognitive changes, delivering results in seconds with demonstrated accuracy exceeding 85% for BAC prediction and approximately 88% for intoxication classification, as validated through controlled studies and real-world testing.

To support enterprise adoption, MindBio is developing an integrated Edge AI hardware-software platform, including voice-initiated, touchless kiosk-based systems for on-site deployment with real-time, on-device analysis and audit-ready data capture for compliance. The platform is designed to support both hardware sales and recurring software revenue, while also expanding into adjacent applications such as telehealth, remote monitoring, and multi-substance detection using the same underlying voice analysis technology.

Market Opportunity

MindBio is targeting a total addressable market of approximately $47 billion in workplace safety and substance testing, driven by regulatory requirements across industries such as mining, aviation, construction, and transportation. The global workplace drug testing market is estimated at $15.4 billion, reflecting continued demand for solutions that can improve efficiency, scalability, and compliance in safety-critical environments.

The company also operates within broader high-growth markets, including telehealth and remote monitoring, projected to reach $285 billion, and consumer health applications estimated at $18.2 billion. These opportunities are supported by larger trends in digital health and alcohol-related harm, including a $547 billion digital health market and an estimated $1.6 trillion global cost associated with alcohol-related harm, reinforcing demand for scalable, non-invasive diagnostic technologies.

Leadership Team

Justin Hanka, Founder & CEO, brings a background in merchant and investment banking, with multiple successful exits and a focus on advancing technologies that have a meaningful impact on global health outcomes.

Gavin Upiter, Non-Executive Chairman, brings more than 25 years of experience in the pharmaceutical industry, including founding Generic Health, which was later sold to Lupin.

John Dinan, CFO, brings experience as a public and private company chief financial officer, with expertise in private equity and mergers and acquisitions, as well as a background as an Olympic sprinter and record holder.

Paul Lopez, Chief Engineer, brings more than 20 years of experience working with leading technology companies, with expertise in artificial intelligence and software design, and leads the company’s global engineering team.

MindBio Therapeutics Corp. (OTCQB: MBQIF), closed Wednesday's trading session at $0.8586, even for the day. The average volume for the last 3 months is 10,950 and the stock's 52-week low/high is $0.28/$2.4435.

Recent News

• MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) - BioMedNewsBreaks - MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF) Engages Venture Liquidity Providers for Market-Making Services
• MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) Offers World's First Voice-Enabled AI-Powered Drug and Alcohol Platform for Workplace Substance Abuse Screening
• TechMediaBreaks - MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF) Develops Intox Collect(TM) to Scale AI Voice-Based Intoxication Detection